Results 151 to 160 of about 59,816 (256)

Successful Management of Fetal Supraventricular Tachycardia With Flecainide in a Case Complicated by Early Hydrops Fetalis: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Fetal arrhythmia that can lead to hydrops fetalis and fetal heart failure if untreated. This case report describes the successful treatment of a fetus with SVT at 26 weeks of gestation using flecainide. A 37‐year‐old gravida 3, para 2 woman was diagnosed with fetal SVT during a routine ultrasound, which also revealed mild pleural effusion ...
Amirabbas Faridpour, Yazdan Ghandi, Alireza Golbabaei   +2 more
wiley   +1 more source

Acute Systemic Complications Following High‐Dose Semaglutide Reinitiation in an Elderly Patient

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Severe gastrointestinal intolerance with systemic complications can occur within hours of reinitiating high‐dose semaglutide after a prolonged treatment interruption, even in patients who previously tolerated the medication. Elderly patients with comorbidities may be particularly vulnerable.
Jay Mehta, Brent Tai, Johnathan Frunzi
wiley   +1 more source

Flecainide‐Induced Interstitial Lung Disease: A Case Report and Review of the Literature

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT This case describes a rare adverse effect in which the subject developed interstitial lung disease after initiating a class IC antiarrhythmic, flecainide. There is no current treatment recommendation for flecainide‐induced interstitial lung disease.
Elizabeth Jenkins, John McGinty, Brian Skinner   +2 more
wiley   +1 more source

Two Cases of Kounis Syndrome Caused by Contrast Medium: Early Extracorporeal Membrane Oxygenation

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In cardiology, Kounis syndrome (KS), also known as allergic angina or myocardial infarction, is often overlooked in emergencies. Its pathophysiology differs from that of allergic reactions such as anaphylaxis, making differentiation essential.
Kiichi Yano, Yu Asami, Takumi Inoue, Emiko Takego, Kenji Tamai, Hiroyuki Takahashi   +5 more
wiley   +1 more source

Acute eosinophilic pneumonia induced by amiodarone: a rare case with early-onset. [PDF]

World J Emerg Med
Zhang L, Zhang T, Zhou M, Chen J.
europepmc   +1 more source

Daily Remote Monitoring of Pediatric Patients With Cardiac Implantable Electronic Devices: Early Arrhythmia Detection and Timely Clinical Intervention

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In recent years, significant progress has been made in the management of pediatric arrhythmias through the use of cardiac implantable electronic devices (CIEDs) such as pacemakers (PMs) and implantable cardioverter‐defibrillators (ICDs).
Piotr Wieniawski, Jakub Zabłocki, Bożena Werner   +2 more
wiley   +1 more source

Reversible massive ascites from amiodarone hepatotoxicity. [PDF]

Oxf Med Case Reports
Nishimura Y, Horiuchi Y, Tanabe K.
europepmc   +1 more source

An Evaluation of Longitudinal Thyroid Hormone Levels Over the Years Before and After Patients Started on Levothyroxine

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
Free thyroxine (FT4) median (interquartile range) and percentage FT4 within reference range for patients pre‐ and post‐levothyroxine (LT4) treatment versus untreated individuals. ABSTRACT Introduction This retrospective study aimed to investigate how free thyroxine (FT4) and thyroid‐stimulating hormone (TSH) levels change in the years pre‐ and post ...
Michael Stedman, Peter Taylor, Ian Halsall, David Halsall, Buchi Okosieme, Suhani Bahl, Sangeeth Veluchamy, Lakdasa Premawardhana, Anthony A. Fryer, Colin Dayan, Adrian Heald   +10 more
wiley   +1 more source

Sequential Amiodarone-Induced Thyroid Dysfunction: From Myxedema Coma to Late-Onset Type 1 Thyrotoxicosis After Drug Withdrawal. [PDF]

Clin Case Rep
Soares DM, Ferreira L.
europepmc   +1 more source

Pleuritis Induced by Brigatinib During the Treatment of Non‐Small Cell Lung Cancer

Respirology Case Reports, Volume 14, Issue 5, May 2026.
This is the first reported case of brigatinib‐induced pleuritis in ALK‐positive lung cancer. Pleural effusion resolved after discontinuation and did not recur at a reduced dose of 30 mg/day. Dose reduction to 30 mg/day could be a safe and effective management strategy in selected patients.
Shohei Yano, Moon Hee Hwang, Tomoko Harima, Shota Takahashi, Takumi Yamada, Nao Yoshida, Yuki Yoshida, Atsushi Hirai   +7 more
wiley   +1 more source